Meet the inventors of liver support ...


Key figures

Albutec GmbH was founded in 2004. Our mission: To advance ECAD to the next stage. Therefore, we developed a proprietary platform technology for effective liver support that performs best in class detoxification in an extracorporeal set-up with the utmost safety and usability. Our technology is protected by several granted and pending patents worldwide.

Albutec is a research and development company with a seasoned team of professionals gathering decades of experience in liver support.

Our company is based in the Hanseatic city of Rostock, Germany at the Biomedical Research Center. Albutec is DIN EN ISO 13485 certified. It has authorization for wholesale trade in medicinal products in accordance with § 52 AMG (German Medicines Act).

Spoken Languages
English, German, Swedish
Team Members

liver support


Removal of Stabilizers


Recycled Albumin (20% Solution)

300.000 litres

What We Be-lieve

Company profile

The idea

In line with our mission to enhance extra corporal albumin dialysis to the next stage we started our research & development project on a new set-up combining optimized flow dynamics and refined components. Funded by grants in pre-seed we initiated fundraising and completed seed phase financing in 2008. Successful feasibility studies resulted in the Hepalbin®-Adsorbent, which easily removed unwanted stabilizers from human albumin solutions to enhance albumin binding capacity significantly.

Further development

Based on promising in vitro data, we continued to evolve our technology. Testing a variety of prototypes our efforts paid off - We improved the nano structured Hepalbin®-Adsorbent for bed-side removal of contaminations and to prepare large albumin pools for albumin dialysis. 
The new CE certified infusion device became the worldwide first technology for applying human albumin solutions without caprylate and acetyltryptophanate, which is most important for patients with liver failure. Achieving this fundamental milestone enabled Albutec to complete Series A financing to proceed to the next stage in albumin dialysis.

Go to market

After launching the CE marked Hepalbin®-Cluster12 for albumin dialysis in 2013 we initiated a clinical trial to validate and compare performance data. Demonstrating superiority and significance in survival and recovery led to thousands of successful treatments. Motivated by these results exceeding our expectations we constantly enhanced our technology introducing the all-new modular Hepalbin MaxiCycler to the market in Q4 2021. Based on that latest innovation we are preparing our Series B financing in early 2022 to receive the next steps in our roll-out strategy for Europe and the US.

Our Misson

To advance ECAD to the next stage.

Meet the inventors of liver support with decades of experience in extracorporeal treatments. The seasoned team is prepared to deliver clinical & commercial success and we are proud of our grown and strengthened relationship with EU authorities and FDA to keep up with the regulatory world.

Our knowledge to handle complex technologies but, at the same time understanding the need for usability and simplicity in daily clinical business is the ultimate base to constantly enhance our products. Supported by a seasoned board of advisors and a well-established network of noted liver experts we are focusing one goal – To sustainably improve the life of patients suffering from liver diseases.

who we are

Our Team

Dipl.-Med. Katrin Stange

Chief Executive Officer

Phone: +49 381 128 6985

Prof. Dr. med. Jan Stange

Chief Medical Officer

Phone: +49 381 1286987

Dr. rer. hum. Peter Gierschner

Responsible Person (Biotechnologist)

Phone: +49 381 121 65875

Jan Klaiber

Sales & Commercialization

Phone: +49 381 494 7330

Stine Koball

R&D Scientist (Biotechnologist)

Phone: +49 381 121 65873

Filip Neubert

Medical Documentalist

Phone: +49 381 121 65871

Malte Garling

Quality Assurance & Logistics

Phone: +49 381 121 65872

Anna Stange

Quality Manager

Phone: +49 381 121 65873

Phillip Barkow

Head of Production

Phone: +49 381 121 65875